Cancer control

This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Education, Science and Culture, a grant for the Program for a Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan, grants from the Foundation for Promotion of Cancer Research, the Princess Takamatsu Cancer Research Foundation, and the Smoking Research Foundation., and by Grant CA 12623 from the National Institutes of Health. 

Development and implementation of prospective medical surveillance system for cancer control involving 1,200 active employees, 5,500 previous employees and 3,500 family members of employees from 1974... 

Lepkowski, W., The Limits to Cancer Control, Nature, in press. 

Tobacco Control Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd, EPN 4048, MSC 7337, Bethesda, MD 20892-7337, USA djordjev mail.nih,gov... 

IARC s mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. 

Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer controlled trial of preoperative radiotherapy and radical cystectomy versus radical cystectomy. BrJ Urol 1982 54 136-151. 

Burns EA and Leventhal EA. Aging, immunity, and cancer. Cancer Control 2000 7 513-522. 

The possibility of moderating the response of cells to a particular mutagen by natural substances opens new horizons in cancer control. On this basis, the research for antimutagens could bring about surprises in the discovery of new anticarciongenic substances. 

When epidemiological data are available, the issues to be dealt with include selection of the appropriate study and control populations, evaluation of exposure levels and tissue doses, determination of the reliability of cancer ascertainment, allowance for the latent period and age distribution of cancers, control of biases and confounding factors, fitting of models to the data to characterize the dose-incidence relationship, and derivation of risk estimates with their associated ranges of uncertainty. 

Lawson DH Choices in adjuvant therapy of melanoma. Cancer Control 2005 12 236. [PMID 16258495]... 

Using data collected in the population-based case-control study of cancer among male residents of Montreal, Canada, described in the monograph on dichloromethane (see this volume), Gerin et al. (1998) carried out an analysis focusing on cancer risks in relation to benzene, toluene, xylene (see this volume) and styrene exposure. For these analyses, the control group for each case series consisted of a combination of the 533 population controls with 533 cancer controls selected at random from the pool of eligible cancer controls. Fifteen per cent of the entire study population had been exposed to toluene at... 

Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (Velcade), a peptidyl boronic acid which is a reversible (0.6 nM Ki) proteasome inhibitor is currently in use and approved for the treatment of multiple myeloma. In addition, there are numerous ongoing clinical trials on the use of this agent for treatment of other malignant diseases Cancer Control 10 361... 

Boyle P, Leon ME, Maisonneuve P, Autier P. Cancer control in women. Update 2003. IntJ Gynaecol Obstet. 2003 83(suppl l) 179-202. 

G. Braslawsky. 2002. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 9 152-166. 

FrBhlich, H. IEEE Trans. MTT-S, Special Issue on Microwaves in Medicine, with Accent on the Application of Electromagnetics to Cancer Control", 1978. 

Lyman GH, Kuderer N, Agboola O, Balducci L. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003 10 487-99. 

Another potentially curative application of expanded porphyrins is to use them as sensitizers in X-ray tumor therapy (XRT). While so far only proposed in the context of the gadolinium(III) texaphyrin system 10.2, such a use is one that carries within it the possible seeds of enormous societal benefit. This is because it would allow one of the most important of all cancer control strategies, namely radiation therapy, to be made more efficacious. 

Venkattaramanabalaji GV, Foster D, Greene JN, Muro-Cacho CA, Sandin RL, Saez R, Robinson LA. Mucormycosis associated with deferoxamine therapy after allogeneic bone marrow transplantation. Cancer Control 1997 4(2) 168-71. 

Dalton WS. Anemia in multiple myeloma and its management. Cancer Control 1998 5(2 Suppl l) 46-50. 

The agency s research concentrates on the occurrence, causes, treatment, and prevention of cancer. It does not develop cancer control policies or implement cancer control measures except where this is necessary to achieve its research objectives. 

Sakamoto K, Myojin M, Hosoi Y, Ogawa Y, Nemoto K, et al. 1997. Fundamental and clinical studies on cancer control with total or upper half body irradiation. J. Jpn. Soc. Ther. Radiol. Oncol. 9 161-75... 

Robson ME. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control 2002 9 457-65. 

Lake DE, Hudis C. Aromatase inhibitors in breast cancer an update. Cancer Control 2002 9 490-8. 

Cancer Control Journal http //www.moffitt.usf.edu/ Published by the H. Lee Moffitt... 

---